Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor

The dismal prognosis of pediatric and young adult patients with high-risk rhabdomyosarcoma (RMS) underscores the need for novel treatment options for this patient group. In previous studies, the tumor-associated surface antigen ERBB2 (HER2/neu) was identified as targetable in high-risk RMS. As a pro...

Full description

Bibliographic Details
Main Authors: Leonie D. H. Gossel, Catrin Heim, Lisa-Marie Pfeffermann, Laura M. Moser, Halvard B. Bönig, Thomas E. Klingebiel, Peter Bader, Winfried S. Wels, Michael Merker, Eva Rettinger
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
RMS
ERBB2
HER2/neu
NK-92
CAR
cancer immunotherapy
Online Access:https://www.mdpi.com/2072-6694/13/6/1443

Similar Items

Similar Items